Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [ 13C]pantoprazole breath test

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 297-305

  Desta, Zeruesenay ^a   Modak, Anil ^b   Nguyen, Phuong D ^a   Lemler, Suzanne M ^a   Kurogi, Yasuhisa ^b,c   Li, Lang ^a   Flockhart, David A ^a  

^a INDIANA UNIVERSITY   (United States)

^b CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

^c Otsuka Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CARBON 13; CARBON DIOXIDE; CYTOCHROME P450 2C19; GENOMIC DNA; PANTOPRAZOLE; PANTOPRAZOLE C 13; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; EXPIRED AIR; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INFRARED SPECTROSCOPY; ISOTOPE LABELING; LIVER CELL; LIVER LEVEL; MALE; NON INVASIVE PROCEDURE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CARBON DIOXIDE; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 63849163983     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.147751     Document Type: Article

References (39)

1. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacoki-net 31:9-28.
2. Andersson T and Weidolf L (2008) Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28:263-279.
3. Ando Y, Fuse E, and Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973.
4. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, and Goldstein JA (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12: 703-711.
5. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
6. Desta Z, Zhao X, Shin JG, and Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958.
7. Ferron GM, Ku S, Abell M, Unruh M, Getsy J, Mayer PR, and Paul J (2003) Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health Syst Pharm 60:1324-1329.
8. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, and Branch RA (2006) Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 80:235-245.
9. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, and Kaneko E (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027-1030.
10. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, and Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561.
11. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, and Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor- based therapies. Drug Metab Pharmacokinet 20:153-167.
12. Furuta T, Sugimoto M, Shirai N, and Ishizaki T (2007) CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 8:1199-1210.
13. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, and Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234 -242.
14. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, and Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double- blind OCLA(Omeprazole CLopidogrel Aspirin) study. JAm Coll Cardiol 51:256-260.
15. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349 -355.
16. Goldstein JA and de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
17. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, and Evans DA (1997) Frequencies ofthe defective CYP2C19 alleles responsible for the mepheny-toin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
18. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, and Mizugaki M (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596 -603.
19. Howden CW (2005) Review article: immediate-release proton-pump inhibitor therapy-potential advantages. Aliment Pharmacol Ther 22 (Suppl 3):25-30.
20. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247.
21. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, and Tateishi T (2005) The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44:1179 -1189.
22. Kupfer A, Desmond PV, and Schenker SBR (1979) Family study of a genetically determined deficiency of mephenytoin hydroxylation in man (letter). Pharmacologist 21:173.
23. Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, and Droździk M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877-880.
24. 13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol 48:1041-1051.
25. Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, Chen Y, and Zhou L (2007) Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 92:1246-1249.
26. MattisonLK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, and Diasio RB (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10:2652-2658.
27. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, et al. (2003) Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 59:553-557.
28. 13C breath tests: transition from research to clinical practice, in Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring (Amann A and Smith D eds) pp 457-478, World Scientific, Singapore.
29. Rudberg I, Mohebi B, Hermann M, Refsum H, and Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327.
30. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, and Ingelman- SundbergM(2006)AcommonnovelCYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113.
31. Sugimoto K, Uno T, Yamazaki H, and Tateishi T (2008) Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65:437-439.
32. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, and Illei GG (2004) Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50:2202-2210.
33. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui H, Yamamori S, and Ishizaki T (1997a) Metabolic disposition of panto-prazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 62:619-628.
34. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, and Ishizaki T (2001) Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 69:108-113.
35. Tanaka M and Yamazaki H (1996) Direct determination of pantoprazole enanti-omers in human serum by reversed-phase high-performance liquid chromatography using a cellulose-based chiral stationary phase and column-switching system as a sample cleanup procedure. Anal Chem 68:1513-1516.
36. Tanaka M, Yamazaki H, Hakusui H, Nakamichi N, and Sekino H (1997b) Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole: a preliminary study. Chirality 9:17-21.
37. Wrighton SA, Stevens JC, Becker GW, and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
38. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, and Wood AJ (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539 -549.
39. Yin OQ, Tomlinson B, Chow AH, Waye MM, and Chow MS (2004) Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 44:582-589.